Current Molecular Medicine

David W. Li  
College of Medicine
University of Nebraska Medical Center
Omaha, NE


Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions

Author(s): J. P. Murad, O. A. Lin, E. V. Paez Espinosa and F. T. Khasawneh

Affiliation: Department of Pharmaceutical Sciences, Western University of Health Sciences, 309 E. Second St., Pomona, CA 91766, USA.


The premise of targeted therapy was born from an intimate understanding of the unique biological pathways and endpoints which are implicated in the development of different disease states and conditions. In addition, the identification of the most appropriate drugs to use for targeted drug therapy has aided in growing interest of the pharmaceutical industry to allocate more resources to monoclonal antibody (mAb) therapeutics. This being the case, it is important to understand antibody based therapeutics, some of the currently Food and Drug Administration (FDA)-approved mAbs in different disease states, as well as the future direction of mAb therapies. In this article, we will provide a critical overview, and discuss a selection of antibody based therapeutics, including their bioengineered structural and functional elements. Furthermore, a segment of the currently FDA-approved mAb antibody therapies, those in research, or in investigation for disease states and conditions ranging from autoimmune disease, inflammatory response, immunosuppression, cancer, including antibody-drug conjugates, immunotherapy, and exciting prospects for antiplatelet and antithrombotic monoclonal antibody therapeutics will be reviewed. Finally, we will discuss our predictions and aspirations for the future directions of mAb-based therapeutic interventions.

Keywords: Antibody, antibody based therapeutics, antithrombotic agents, immune response, monoclonal antibodies

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [165 - 178]
Pages: 14
DOI: 10.2174/1566524011307010165